Advanced Search

 

Study ID Status Title Patient Level Data
101695 Ext. Mth30 Completed Long-term study of immune response persistence of GSK Biologicals' 2-dose thiomersal-free Engerix™-B and 3-dose preservative-free Engerix™-B vaccines in subjects aged 11-15 yrs Study Listed on ClinicalStudyDataRequest.com
101724 Completed A randomized, double blind, double dummy, parallel group, placebo controlled study to evaluate the pharmacodynamic and pharmacokinetic response and safety and tolerability of SB424323 (250mg, 375mg and 500 mg) administered twice daily for 16 weeks, on top of asprin (325mg, qd) in men and women with non valvular atrial fibrillation at a low or intermediate risk for stroke
101765 Completed Comparison of the action of the rosiglitazone-metformin fixed-dose combination and of a metformin-sulfonylurea free combination on the b-cell function in type 2 diabetic patients not controlled with metformin alone.
101822 Completed A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
101858 Completed Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 years Study Listed on ClinicalStudyDataRequest.com
101909 Completed A single blind, randomised, placebo controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of GSK206136 in healthy male subjects and an open label Positron Emission Tomography study to evaluate the serotonin transporter and neurokinin-1 receptor occupancy
101957 Completed A randomized, open label study to compare the safety and efficacy of a long term maintenance with TRIZIVIR after a switch from a boosted PI or a NNRTI as first line therapy for 96 weeks.
102039 Completed Evaluate the safety, reactogenicity and immunogenicity of 2 antigen dose levels of GSK Biologicals’ candidate tuberculosis vaccine, Mtb72F/AS02 to healthy PPD-negative volunteers aged 18 to 45 years
102115 Completed A dose-range study to assess the safety and immunogenicity of a novel HPV vaccine when administered intramuscularly according to a 3-dose schedule (0,1,6-month) in healthy adult females (18-25 years of age) Study Listed on ClinicalStudyDataRequest.com
102238 Completed A multicenter, open-label Phase I/II trial to evaluate the safety and activity of CPC-P501 protein formulated with the adjuvant AS15 as first-line treatment in patients with hormone-sensitive prostate cancer who show rising PSA
102247/036 Completed A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines Study Listed on ClinicalStudyDataRequest.com
102248 Completed Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants Study Listed on ClinicalStudyDataRequest.com
102318 Completed Steroid-sparing management of the salmeterol/fluticasone 50/100µg b.i.d. combination compared to fluticasone 200µg b.i.d. in children and adolescents with moderate asthma Study Listed on ClinicalStudyDataRequest.com
102370 (primary study) Completed A multicentre primary & booster vaccination study of GSK Biologicals' Hib-MenCY-TT conjugate vaccine vs ActHIB® & MenC conjugate licensed vaccine when given according to the 2-4-6 month schedule to healthy infants with booster dose at 12 to 15 months Study Listed on ClinicalStudyDataRequest.com
102374 Completed Double-blind (observer-blind), randomised, controlled, phase I/II study, to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate tuberculosis vaccine, Mtb72F/AS02A administered intramuscularly at 0, 1, 2 months to healthy PPD-positive volunteers aged 18 to 50 years
102394 Completed A Phase IV, partially double-blind study to demonstrate non-inferiority of GSK Biologicals’ Mencevax™ ACWY (new process) versus Mencevax™ ACWY (current process) when administered as a single dose to subjects aged 2-30 yrs Study Listed on ClinicalStudyDataRequest.com
102487 Completed A Single Dose Study to Assess the Effect of Non-Bioenhanced, Non-Enteric Coated, Freebase SB-659032 on Platelet Function in Healthy Adult Subjects
102499 Completed A phase III, open, randomized, multicenter, comparative vaccination study to evaluate the immunogenicity and reactogenicity of various formulations of a monovalent candidate pandemic influenza A vaccine in individuals over 60 years of age Study Listed on ClinicalStudyDataRequest.com
102547 Completed Evaluate immunogenicity,safety & reactogenicity of a booster dose of Hib-MenC conjugate vaccine when given to healthy subjects aged 13-14 months who were primed with 3 doses of Hib-MenC vs a booster dose of Infanrix hexa given to subjects primed with 3 doses of Infanrix hexa and Meningitec Study Listed on ClinicalStudyDataRequest.com
102577 Completed A Phase I, Open-Label, 2-Period, Single-Sequence, Drug Interaction Study to Assess Steady-State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD with Fosamprenavir 700mg BID + RTV 100mg BID in Opiate-Dependent, HIV Seronegative, Adult Subjects
102747 Terminated Investigation of the NMDA receptor system in man as a potential surrogate marker for deficit syndrome in schizophrenia: a [123]I-CNS 1261 single photon emission tomography (SPET) study
102871 Completed HZC102871: A 52-week efficacy and safety study to compare the effect of three dosage strengths of Fluticasone Furoate/GW642444 Inhalation Powder with GW642444 on the Annual Rate of Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Study Listed on ClinicalStudyDataRequest.com
102881 Terminated A PhaseIIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, PK and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults
102932 Completed An open-label, randomised, 3-way crossover single dose study to demonstrate dose proportionality of fluticasone furoate (FF) and equivalence of vilanterol (VI) when administered as FF/VI inhalation powder from the novel dry powder inhaler in healthy subjects. Study Listed on ClinicalStudyDataRequest.com
102934 Completed An open-label, non-randomised, three-way crossover, single dose study to determine the absolute bioavailability of fluticasone furoate (FF)/GW642444 Inhalation Powder, in healthy subjects Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.